Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 3/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075190 | 0.88 | CYP2D6 (0.42) | ALDH1A1KDM4EHPGDPPARGPPARD | |
| SCHEMBL29937490 | 0.82 | KCNA3 (0.34) | KDM4E | |
| SCHEMBL7076825 | 0.81 | MTNR1A (0.42) | ALDH1A1KDM4EHPGDMTNR1AMTNR1B | |
| SCHEMBL7080458 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDNPC1LMNA | |
| SCHEMBL4423987 | 0.78 | NQO2 (0.39) | ALDH1A1KDM4EHPGDNPC1 | |
| SCHEMBL7082367 | 0.78 | PPARG (0.42) | ALDH1A1KDM4EPPARGPPARDPPARA | |
| SCHEMBL4421534 | 0.77 | PPARA (0.41) | ALDH1A1KDM4EPPARGPPARA | |
| SCHEMBL29344208 | 0.77 | CYP1A2 (0.40) | ALDH1A1KDM4EHPGDNPC1LMNA | |
| SCHEMBL6041625 | 0.76 | PKM (0.35) | ALDH1A1KDM4EHPGDRENNPC1 | |
| SCHEMBL6041493 | 0.76 | CDC25B (0.40) | ALDH1A1KDM4ENPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495001-B2 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1682507-A1 | BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049572-A1 | BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096336-A1 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096336-A1 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | ALDH1A1 714/4885KDM4E 1857/4885HPGD 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.